CytomX Therapeutics, Inc.
CTMX Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.23
KIRA · Stoqly’s AI analyst, in plain words
- CytomX Therapeutics, Inc. had $76.2M of revenue in fiscal 2025, down 44.8% on the year before. Over five years, revenue changed +2.2% a year on average.
- Its operating margin was −29.3%, down 47.4 pts: of every 100 in sales, about −29 is left after running the business.
- CytomX Therapeutics, Inc. lost $17.4M in fiscal 2025.
- Free cash flow was −$75.8M in fiscal 2025, −99.5% of revenue.
Market cap
$487M
P/E
—
Revenue
$76.2M
Net income
−$17.4M
Free cash flow
−$75.8M
Operating margin
−29.3%
CytomX Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−44.8%
No. Sales fell 44.8% last year.
Does it make a profit?
−22.8%
No. It lost money last year.
Does profit turn into cash?
−99.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
What CytomX Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- CytomX Therapeutics, Inc.
- CIK
- 0001501989
CytomX Therapeutics, Inc. · CTMX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $37.3M | $53.2M | $101M | $138M | $76.2M |
| Revenue growth | −45.5% | 42.5% | 90.4% | 36.4% | −44.8% |
| Operating margin | −311.0% | −190.6% | −6.4% | 18.1% | −29.3% |
| Net income | −$116M | −$99.3M | −$0.6M | $31.9M | −$17.4M |
| Net margin | −310.5% | −186.8% | −0.6% | 23.1% | −22.8% |
| Cash | |||||
| Cash from operations | −$119M | −$111M | −$56.0M | −$86.2M | −$75.6M |
| Capital expenditure | $1.6M | $1.7M | $0.8M | $0.3M | $0.2M |
| Free cash flow | −$121M | −$113M | −$56.9M | −$86.5M | −$75.8M |
| FCF margin | −323.3% | −211.7% | −56.2% | −62.7% | −99.5% |
| Share count change | 39.0% | 2.5% | 12.3% | 14.8% | 62.8% |
| Debt and strength | |||||
| Cash and short-term investments | $305M | $194M | $175M | $101M | $137M |
| Shareholders' equity | −$0.5M | −$85.8M | −$47.4M | −$0.5M | $99.0M |
| Current ratio | 4.0x | 1.6x | 1.2x | 1.3x | 3.1x |
| Returns and quality | |||||
| Return on equity | — | — | — | — | −35.2% |
| Return on tangible equity | — | — | — | — | −20.8% |
| Piotroski F-score | 0 | 1 | 2 | 4 | 1 |
| Altman Z'' | −3.8 | −9.8 | −11.2 | −16.1 | −10.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.7M
4 insiders
Of sales under plans
72%
$1.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
CytomX Therapeutics, Inc. · CTMX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.23 a share, the company is worth $487M.
Source: SEC EDGAR XBRL filings (CIK 0001501989). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.